Bloomberg News reported on the 23rd that yogurt sales in the U.S. have increased as products such as WeGobee and Ozempic have gained popularity as obesity treatments. According to reports, Danone, a global food company headquartered in France, said that demand for high-protein, low-calorie yogurt has recently been increasing in the United States, and that this is partly due to the craze for obesity treatment drugs such as Wegobee and Zebbound. J\u00fcrgen Esser, Danone’s vice president of finance, said, “We have a wide range of protein yogurt products, which are selling like hot cakes recently.” \u201cIt is popular with all consumers who want to manage their health,\u201d he said. GLP-1 is a hormone secreted from the intestines when food is consumed and helps suppress appetite by promoting insulin secretion, which is important in controlling blood sugar levels. It is evaluated as a \u2018game changer\u2019 in the obesity treatment market because it allows you to feel full for a long time even with a small meal. Bloomberg reported that this change in sales occurred even though Danone did not engage in special marketing targeting consumers receiving obesity treatment. Nestle, a multinational food company, is also developing and releasing customized products targeting obesity treatment consumers. Nestl\u00e9 announced last month that it was launching a new food line called ‘Vital Pursuit’, rich in fiber and protein, for consumers taking Ozempic or WeGobee. It is estimated that approximately 30 million Americans are currently taking GLP-1. Experts predict that the consumption patterns of many consumers will change, such as reducing food intake and changing their diets, which will have an impact on various industries, including the retail and restaurant industries.<\/p>\n","protected":false},"excerpt":{"rendered":"